The United Laboratories International Holdings (UNJ) Stock Price & Analysis
UNJ Stock Chart & Stats
- Day’s Range
- EUR 0.77 - EUR 0.77
- 52-Week Range
- EUR 0.75 - EUR 1.50
- Previous Close
- EUR 0.77
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 1.53B
- Enterprise Value
- EUR 10.04B
- Total Cash (Recent Filing)
- EUR 11.73B
- Total Debt (Recent Filing)
- EUR 5.95B
- Price to Earnings (P/E)
- 21.1
- Beta
- 0.55
- Next Earnings
- Mar 30, 2027 (Est.)
- EPS Estimate
- 0.03
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.95%
Bulls Say, Bears Say
Bulls Say
Diversified Pharmaceutical Model
The combination of finished medicines and API production gives the company multiple revenue streams across the pharmaceutical value chain. This diversification can support manufacturing scale, broaden customer exposure, and reduce reliance on any single product category over the next several quarters.
Conservative Balance Sheet
Moderate leverage and steadily expanding equity provide a relatively solid financial base for a pharmaceutical manufacturer. This supports continued investment in products and capacity while preserving more flexibility to manage weaker earnings or cash generation over the medium term.
Strong Underlying Profitability
Despite recent compression from prior peaks, the company continues to generate substantial gross and net margins. This indicates that its product portfolio still produces meaningful economic value and provides an earnings cushion while management works through slower growth and lower returns.
Bears Say
Revenue And Margin Deterioration
The combination of falling revenue and lower margins weakens earnings momentum and makes future growth less dependable. If this trend persists, reduced operating leverage could limit reinvestment capacity, weaken returns, and make it harder for the company to sustain prior profitability levels.
Weak And Volatile Cash Conversion
Low conversion of reported profit into free cash flow raises concern about earnings quality and the funds available for investment, debt reduction, or shareholder returns. Volatile cash generation also makes financial planning less predictable and increases reliance on balance-sheet resources.
Lower Returns With Higher Debt
Higher debt alongside materially weaker return on equity suggests that the company is generating less profit from its capital base while carrying greater obligations. Although leverage remains moderate, this combination could constrain capital efficiency and amplify pressure if operating performance stays weak.
The United Laboratories International Holdings News
UNJ FAQ
What was The United Laboratories International Holdings’s price range in the past 12 months?
What is The United Laboratories International Holdings’s market cap?
When is The United Laboratories International Holdings’s upcoming earnings report date?
How were The United Laboratories International Holdings’s earnings last quarter?
Is The United Laboratories International Holdings overvalued?
Does The United Laboratories International Holdings pay dividends?
What is The United Laboratories International Holdings’s EPS estimate?
How many shares outstanding does The United Laboratories International Holdings have?
What happened to The United Laboratories International Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of The United Laboratories International Holdings?
What is the TipRanks Smart Score and how is it calculated?
The United Laboratories International Holdings Stock Smart Score
Company Description
The United Laboratories International Holdings
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Hoi Shan Tsoi
- Employees
- 18,000
- Website
- www.tul.com.cn
- Address
- HK
The United Laboratories International Holdings (UNJ) Earnings & Revenues
UNJ Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 1 | 0 | 11 |
